X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7710) 7710
Book Review (1192) 1192
Publication (688) 688
Book Chapter (34) 34
Conference Proceeding (24) 24
Magazine Article (14) 14
Book / eBook (8) 8
Dissertation (2) 2
Data Set (1) 1
Newspaper Article (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (6588) 6588
humans (4922) 4922
adenine - analogs & derivatives (3512) 3512
male (2824) 2824
animals (2764) 2764
adenine - therapeutic use (2532) 2532
female (2194) 2194
organophosphonates - therapeutic use (1854) 1854
tenofovir (1692) 1692
adult (1579) 1579
middle aged (1310) 1310
pharmacology & pharmacy (1289) 1289
antiviral agents - therapeutic use (1233) 1233
adenine (1054) 1054
hiv infections - drug therapy (1052) 1052
adenine - pharmacology (1011) 1011
rats (953) 953
hepatitis b, chronic - drug therapy (941) 941
mice (934) 934
anti-hiv agents - therapeutic use (913) 913
lamivudine - therapeutic use (833) 833
treatment outcome (802) 802
infectious diseases (749) 749
drug therapy, combination (738) 738
biochemistry & molecular biology (731) 731
adenine - administration & dosage (691) 691
lamivudine (636) 636
adenine - adverse effects (615) 615
apoptosis (599) 599
analysis (592) 592
reverse transcriptase inhibitors - therapeutic use (569) 569
oxidative stress (560) 560
metabolism (547) 547
immunology (542) 542
proteins (537) 537
cell biology (518) 518
gastroenterology & hepatology (518) 518
organophosphonates - administration & dosage (516) 516
aged (512) 512
therapy (498) 498
hiv (491) 491
mutation (483) 483
research (480) 480
organophosphonates - adverse effects (475) 475
virology (469) 469
cancer (467) 467
organophosphonates (456) 456
viral load (452) 452
emtricitabine (449) 449
health aspects (448) 448
medicine (447) 447
abridged index medicus (444) 444
hepatitis b virus - genetics (443) 443
mitochondria (443) 443
deoxycytidine - analogs & derivatives (442) 442
hepatitis b (441) 441
time factors (434) 434
nicotinamide adenine dinucleotide (429) 429
guanine - analogs & derivatives (426) 426
multidisciplinary sciences (426) 426
drug therapy (423) 423
article (418) 418
oncology (409) 409
research article (409) 409
enzymes (408) 408
hepatitis b virus - drug effects (407) 407
aids/hiv (402) 402
drug resistance, viral (399) 399
physiological aspects (385) 385
adenine nucleotides - metabolism (372) 372
antiviral agents (372) 372
rodents (372) 372
guanine - therapeutic use (365) 365
infection (359) 359
adolescent (358) 358
deoxycytidine - therapeutic use (355) 355
nad (351) 351
dose-response relationship, drug (345) 345
adefovir dipivoxil (340) 340
science (339) 339
cells (336) 336
dna, viral - blood (335) 335
hepatitis b, chronic - virology (335) 335
inhibition (334) 334
young adult (334) 334
care and treatment (328) 328
anti-hiv agents - administration & dosage (326) 326
anti-hiv agents - adverse effects (326) 326
autophagy (322) 322
dna (322) 322
microbiology (321) 321
gene expression (315) 315
in-vitro (312) 312
purines (305) 305
neurosciences (303) 303
human immunodeficiency virus--hiv (298) 298
organophosphonates - pharmacology (294) 294
disease models, animal (293) 293
nicotinamide (291) 291
cell line, tumor (289) 289
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7262) 7262
Chinese (102) 102
German (83) 83
French (62) 62
Russian (61) 61
Spanish (54) 54
Japanese (42) 42
Italian (24) 24
Korean (19) 19
Czech (9) 9
Hungarian (8) 8
Polish (8) 8
Turkish (7) 7
Dutch (4) 4
Ukrainian (4) 4
Croatian (2) 2
Portuguese (2) 2
Greek (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Infectious Diseases, The, ISSN 1473-3099, 2015, Volume 15, Issue 7, pp. 775 - 784
Summary Background Problems associated with lifelong antiretroviral therapy, such as need for strict adherence, drug-related toxic effects, difficulties with... 
Infectious Disease | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | EFFICACY | SAFETY | NAIVE HIV-1-INFECTED PATIENTS | ACTIVE ANTIRETROVIRAL THERAPY | ONCE-DAILY ATAZANAVIR/RITONAVIR | TWICE-DAILY LOPINAVIR/RITONAVIR | INFECTED PATIENTS | PROTEASE INHIBITORS | TENOFOVIR | HIV-1 | Humans | Middle Aged | Male | RNA, Viral - blood | Viral Load | Oligopeptides - therapeutic use | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Deoxycytidine - therapeutic use | Drug Therapy, Combination - adverse effects | Adenine - therapeutic use | Lamivudine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Pyridines - therapeutic use | Emtricitabine | HIV Protease Inhibitors - adverse effects | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | HIV Infections - virology | HIV Protease Inhibitors - therapeutic use | Drug Therapy, Combination - methods | HIV Infections - drug therapy | Zidovudine - therapeutic use | Drug Substitution | Deoxycytidine - analogs & derivatives | Studies | Antiretroviral drugs | Heart attacks | Protease inhibitors | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Clinical trials | Infections | Mutation | Drug therapy | Failure | Cost control | Index Medicus
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 7/2013, Volume 208, Issue 1, pp. 32 - 39
Background. Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro. Methods. An international, randomized, double-blind,... 
T lymphocytes | HIV/AIDS | Antiretrovirals | Infectious diseases | RNA | HIV | Drug evaluation | AIDS | Photographs | HIV 1 | Virology | cobicistat | pharmacoenhancer | INFECTIOUS DISEASES | CO-FORMULATED ELVITEGRAVIR | RENAL-FUNCTION | INITIAL TREATMENT | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | DAILY LOPINAVIR/RITONAVIR | GLOMERULAR-FILTRATION-RATE | EFAVIRENZ | DOUBLE-BLIND | ONCE-DAILY DARUNAVIR/RITONAVIR | TENOFOVIR | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Thiazoles - therapeutic use | Oligopeptides - therapeutic use | Anti-HIV Agents - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Drug Therapy, Combination | Pyridines - therapeutic use | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Organophosphonates - therapeutic use | Ritonavir - administration & dosage | HIV-1 - drug effects | Deoxycytidine - administration & dosage | Treatment Outcome | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Adenine - administration & dosage | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Carbamates - therapeutic use | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Research | Drug therapy | HIV infection | Patient outcomes | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 229 - 237
Summary Background The non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine (TMC278; Tibotec Pharmaceuticals, County Cork, Ireland), had... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ZIDOVUDINE | COMBINATION THERAPY | ACTIVE ANTIRETROVIRAL THERAPY | EMTRICITABINE | PROTEASE-INHIBITOR | CYSTATIN-C | CREATININE | DAILY LAMIVUDINE | NEVIRAPINE | TENOFOVIR | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Nucleotides - therapeutic use | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Nucleosides - therapeutic use | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Benzoxazines - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Evaluation | Patient outcomes | Clinical trials | Dosage and administration | Drug therapy | HIV infection | Design | Antiretroviral drugs | Corporate sponsorship | Human immunodeficiency virus--HIV | Technological change | Research | Clinical medicine | Drugs | RNA-directed DNA polymerase | Exanthema | antiretroviral therapy | Lamivudine | Lipids | Nucleotides | Regression analysis | Efavirenz | CD4 antigen | nucleosides | Algorithms | Hospitals | non-nucleoside reverse transcriptase inhibitors | Abacavir | Zidovudine | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Science, ISSN 0036-8075, 9/2010, Volume 329, Issue 5996, pp. 1168 - 1174
The Centre for the AIDS Program of Research in South Africa (CAPRISA) 004 trial assessed the effectiveness and safety of a 1% vaginal gel formulation of... 
Human sexual behavior | HIV infections | Antiinfectives | Gels | HIV | RESEARCH ARTICLES | Placebos | Experimentation | AIDS | Infections | Condoms | VAGINAL GEL | INDIVIDUALS | SOUTH-AFRICA | PROPHYLAXIS | IN-VITRO | TRANSMISSION | MULTIDISCIPLINARY SCIENCES | CLINICAL-TRIALS | MALE CIRCUMCISION | RANDOMIZED CONTROLLED-TRIAL | CHALLENGES | HIV Infections - prevention & control | Anti-Infective Agents, Local - therapeutic use | Urban Population - statistics & numerical data | HIV Infections - epidemiology | Humans | Anti-Infective Agents, Local - adverse effects | Drug Resistance, Viral | Administration, Intravaginal | Viral Load | Incidence | Anti-HIV Agents - administration & dosage | Tenofovir | Young Adult | Adenine - adverse effects | HIV-1 - physiology | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Vaginal Creams, Foams, and Jellies | Rural Population - statistics & numerical data | Sexual Behavior | Adenine - analogs & derivatives | Double-Blind Method | Organophosphonates - therapeutic use | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | South Africa - epidemiology | Organophosphonates - adverse effects | Adenine - administration & dosage | Pregnancy | Organophosphonates - administration & dosage | Anti-Infective Agents, Local - administration & dosage | Adolescent | Patient Compliance | Pregnancy Outcome | Prevention | Anti-infective agents | Research | HIV infection | Index Medicus
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 10/2014, Volume 161, Issue 7, pp. 461 - 471
Journal Article
Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 04/2013, Volume 62, Issue 5, pp. 483 - 486
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 238 - 246
Summary Background Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected... 
Internal Medicine | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | COMBINATION THERAPY | GUIDELINES | PROTEASE-INHIBITOR | ANTIRETROVIRAL THERAPY | NEVIRAPINE | REGIMENS | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Dosage and administration | Efavirenz | Patient outcomes | Clinical trials | Antiretroviral drugs | Drug therapy | Human immunodeficiency virus--HIV | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2014, Volume 14, Issue 7, pp. 581 - 589
Journal Article